South Africa launches lenacapavir HIV prevention rollout; long-term adherence key

South Africa begins rollout of lenacapavir, a long-acting injectable HIV-prevention drug, marking a major milestone in HIV prevention. The main uncertainty is whether real-world adherence and follow-up will sustain protection, as the drug's efficacy in trials may not translate to routine use. This matters because South Africa has one of the highest HIV burdens globally, and successful rollout could reshape prevention strategies across the region.